Does UnitedHealth Stock Have More Upside After Q3 Earnings?
Werte in diesem Artikel
UnitedHealth Group's UNH stock hasn’t received the post-earnings rally that investors may have hoped for, but the medical giant was able to provide subtle signs that its operations are stabilizing.Posting mixed but favorable Q3 results on Wednesday, UnitedHealth is striving to overcome a somewhat uphill battle that stems from regulatory scrutiny, leadership instability, and industry headwinds as it relates to rising medical costs. While UnitedHealth stock has rebounded swiftly from a five-year low of $234 a share, UNH is still more than 40% from its 52-week high of $630.Image Source: Zacks Investment Research UnitedHealth’s Mixed Q3 ResultsUnitedHealth’s adjusted Q3 earnings of $2.92 per share comfortably exceeded EPS expectations of $2.75 despite dropping from $7.15 in a tough to compete against prior year quarter. Optimistically, this marked UnitedHealth’s first earnings beat in three quarters, following misses in Q1 and Q2 due to lower Medicare funding and higher care costs, along with exchange losses in its health insurance plans offered through the Affordable Care Act (ACA).That said, Q3 sales of $113.16 billion slightly missed estimates of $113.35 billion, although this was a 12% increase from $100.82 billion a year ago.Image Source: Zacks Investment Research UnitedHealth’s Raised EPS GuidanceSignaling a more optimistic outlook, UnitedHealth raised its full-year adjusted EPS guidance to at least $16.25, up from a previous floor of $16.00. This also came in above the current Zacks Consensus of $16.15.UnitedHealth CEO Stephen Hemsley emphasized “solid earnings growth” in 2026 and beyond, but warned of membership losses in Medicare Advantage and ACA plans. Notably, Hemsley previously headed UnitedHealth from 2006-2017, and was reappointed as CEO in May after his predecessor, Andrew Witty, resigned for personal reasons.Based on Zacks' estimates, UnitedHealth's annual EPS is projected to rebound to $17.39 in fiscal 2026. Image Source: Zacks Investment Research UNH P/E Valuation ComparisonDespite the contraction in its bottom line, UnitedHealth stock still trades at a reasonable 22.7X forward earnings multiple. This is a slight discount to the benchmark S&P 500, and, as a long-time healthcare leader, UNH doesn’t trade at a stretched premium to its Zacks Medical-HMOs Industry average of 18X forward earnings, with some noteworthy peers being Cigna Group CI and Humana HUM.Image Source: Zacks Investment Research UnitedHealth’s Appealing & Reliable DividendAppealing to long-term investors is that UNH offers a respectable 2.4% annual dividend yield that impressively tops the benchmark’s 1.07% average and its industry average of 2.11%.It’s also noteworthy that UnitedHealth is a dividend aristocrat, raising its dividend for at least 25 consecutive years (34). Over the last five years, UNH has an intriguing annualized dividend growth rate of 12.91% and its 35% payout ratio suggests there is plenty of room for more dividend hikes in the future.Image Source: Zacks Investment Research Bottom Line Prioritizing profitability, UnitedHealth is starting to show confidence in its earnings trajectory, which may help UNH shake off the turbulent volatility it saw earlier in the year. For now, UNH lands a Zacks Rank #3 (Hold) as more upside will largely depend on what is hopefully a positive trend of earnings estimate revisions (EPS) for FY26.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Cigna Group (CI): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: UnitedHealth und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf UnitedHealth
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf UnitedHealth
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Zacks
Nachrichten zu UnitedHealth Inc.
Analysen zu UnitedHealth Inc.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
| 15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
| 14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
| 29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
| 17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 14.04.2022 | UnitedHealth Outperform | RBC Capital Markets | |
| 15.10.2020 | UnitedHealth Outperform | Credit Suisse Group | |
| 14.10.2020 | UnitedHealth Outperform | RBC Capital Markets | |
| 29.08.2019 | UnitedHealth Outperform | Credit Suisse Group | |
| 17.07.2018 | UnitedHealth buy | Goldman Sachs Group Inc. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 09.11.2016 | UnitedHealth Group Neutral | Mizuho | |
| 31.03.2011 | UnitedHealth Group perform | Oppenheimer & Co. Inc. | |
| 08.02.2011 | UnitedHealth Group neutral | Goldman Sachs Group Inc. | |
| 15.11.2010 | UnitedHealth Group hold | Stifel, Nicolaus & Co., Inc. | |
| 20.04.2010 | UnitedHealth neutral | Wedbush Morgan Securities Inc. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.06.2009 | UnitedHealth underperform | Oppenheimer & Co. Inc. |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für UnitedHealth Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
